
BrightBid Q1 2025 prel - Soft preliminary ARR – further cost-savings

Redeye comments on the preliminary Q1 figures, the cost-saving program, and the share issue. While the negative ARR trend continued in Q1, with back-to-basics-sales and some financial headroom from the share issue, management seems confident in turning the tide. If successful, the potential is rich.

Read more and download the Research Update.

Follow companies at Redeye to receive the latest equity research within Life Science and Technology.

This is a press release from Redeye - Research Powered Investment Banking. www.redeye.se/

Attachments

BrightBid Q1 2025 prel - Soft preliminary ARR – further cost-savings